Nirrin Technologies’ announcement that Hyaltech, a Carl Zeiss Meditec (XTRA:AFX) subsidiary, has purchased an Atlas system for hyaluronic acid measurement puts fresh attention on how the company is refining manufacturing analytics.

See our latest analysis for Carl Zeiss Meditec.

The Hyaltech Atlas purchase lands at a time when Carl Zeiss Meditec’s share price has picked up short term momentum, with a 1-month share price return of 9.53% and a 90-day return of 15.70%. However, longer term total shareholder returns remain weak, including a 1-year total shareholder return decline of 45.17%.

If this kind of applied healthcare technology story interests you, it may be worth broadening your search to other opportunities in medical AI by checking out 131 healthcare AI stocks

With Carl Zeiss Meditec’s shares rebounding in recent months but longer term returns still weak, the key question now is whether the current valuation reflects a discount to intrinsic value or if the market is already pricing in future growth.

Most Popular Narrative: 5% Undervalued

The most followed narrative currently points to a fair value of €30.19 for Carl Zeiss Meditec, compared with the last close at €28.74, putting more focus on how future cash flows and margins might support that gap.

The recent approval of the VISUMAX 800 in China, earlier than expected, positions Carl Zeiss Meditec AG for potential revenue growth. The launch is expected to boost higher ASP (Average Selling Price) for both devices and treatment packs, enhancing future revenue streams.

Read the complete narrative.

Curious what sits behind that fair value for Carl Zeiss Meditec? The narrative leans heavily on a detailed earnings ramp, firming margins and a future earnings multiple that does not assume blue sky. The key point is how these pieces fit together, and what would need to go right along the way.

Result: Fair Value of €30.19 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Carl Zeiss Meditec still faces pressure from weaker conditions in China and a recently softer product mix. Together, these factors could challenge the current upside narrative.

Find out about the key risks to this Carl Zeiss Meditec narrative.

Next Steps

With sentiment on Carl Zeiss Meditec clearly split between risks and rewards, this is a good moment to review the data yourself and form a view quickly, then weigh both sides through the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Carl Zeiss Meditec?

If Carl Zeiss Meditec has sharpened your interest in focused opportunities, do not stop here. Use targeted stock lists to spot what others might be missing.

• Target higher income potential by reviewing companies in the 479 dividend fortresses that aim to combine yield with resilient cash flows.
• Zero in on value by scanning the 210 high quality undervalued stocks that filters for quality businesses trading below their assessed worth.
• Prioritise resilience by checking the 297 resilient stocks with low risk scores that highlights companies with steadier fundamentals and lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.